Literature DB >> 16464755

Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.

Anita Hill1, Russell P Rother, Peter Hillmen.   

Abstract

Aberrant smooth muscle dystonia during hemolytic episodes in paroxysmal nocturnal hemoglobinuria (PNH) is implicated in the symptoms of abdominal pain, dysphagia and erectile dysfunction. Here we report two PNH patients treated with the complement inhibitor, eculizumab. Complement inhibition has been sustained for over 2 years and results in resolution of intravascular hemolysis and amelioration of symptoms associated with smooth muscle contractions.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16464755

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  10 in total

Review 1.  Updated role of nitric oxide in disorders of erythrocyte function.

Authors:  Marc J Kahn; Jason H Maley; George F Lasker; Philip J Kadowitz
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2013-03-01

2.  Left ventricular assist device hemolysis leading to dysphagia.

Authors:  Alexander Wuschek; Sara Iqbal; Jerry Estep; Eamonn Quigley; David Richards
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

Review 3.  Paroxysmal nocturnal hemoglobinuria in children.

Authors:  Marry M van den Heuvel-Eibrink
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients.

Authors:  Neal S Young; Gabrielle Meyers; Hubert Schrezenmeier; Peter Hillmen; Anita Hill
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

5.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

6.  Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry.

Authors:  Jong Wook Lee; Jun Ho Jang; Jin Seok Kim; Sung-Soo Yoon; Je-Hwan Lee; Yeo-Kyeoung Kim; Deog-Yeon Jo; Jooseop Chung; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-05-01       Impact factor: 2.490

Review 7.  How I treat paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Blood       Date:  2021-03-11       Impact factor: 25.476

Review 8.  Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations.

Authors:  Fatimah Al-Ani; Ian Chin-Yee; Alejandro Lazo-Langner
Journal:  Ther Clin Risk Manag       Date:  2016-08-01       Impact factor: 2.423

9.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12

10.  Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.

Authors:  Peter Hillmen; Petra Muus; Alexander Röth; Modupe O Elebute; Antonio M Risitano; Hubert Schrezenmeier; Jeffrey Szer; Paul Browne; Jaroslaw P Maciejewski; Jörg Schubert; Alvaro Urbano-Ispizua; Carlos de Castro; Gérard Socié; Robert A Brodsky
Journal:  Br J Haematol       Date:  2013-04-25       Impact factor: 6.998
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.